X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing.
Lead Product(s): CAR-T Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CellPoint
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 23, 2021
Details:
The agreement will establish a new production line at Lonza’s Geleen site in the Netherlands, contributing to the supply of an additional 300 million doses of Moderna’s updated booster variant vaccine candidate, Spikevax, if authorized, per year, at a 50 µg dose.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 02, 2021
Details:
Lonza will provide a customized version of the Ibex® Design program to rapidly advance Immunitas' lead program, IMT-009, from development candidate to IND.
Lead Product(s): IMT-009
Therapeutic Area: Oncology Product Name: IMT-009
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunitas Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 15, 2021
Details:
The collaboration will help Gracell leverage Lonza's worldwide integrated services and expertise in CAR-T cell therapy manufacturing. Gracell is advancing its innovative CAR-T pipeline globally for difficult-to-treat cancers, including its lead program for GC012F.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gracell Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021
Details:
Lonza to provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate intended for oncology indications.
Lead Product(s): PY265
Therapeutic Area: Oncology Product Name: PY265
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pionyr Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
